Since longitudinal data, including eosinophil counts obtained over a 20- to 30-year periods in some family members, show remarkable stability in the absolute eosinophil count with no evidence of disease attributable to eosinophil-related tissue injury, therapy to lower eosinophil counts such as corticosteroids, tyrosine kinase inhibitors, and antibodies directed against interleukin 5 have in general not been used to treat<unk> . One patient with severe heart damage was treated with a corticosteroid but soon thereafter died.<unk>  unassociated with possible eosinophil-related tissue injuries may not require drug treatment, those cases with such tissue injuries, it is suggested, should be considered for such interventions. In all cases, however, regular follow-up of the disorder is strongly recommended.
Familial eosinophilia
Tropical eosinophilia
Hypereosinophilic syndrome
Hereditary angioedema
Lymphocyte-variant hypereosinophilia
Mast cell activation syndrome
Drug reaction with eosinophilia and systemic symptoms
Mixed connective tissue disease